Attomarker’s Breakthrough in Long Covid Diagnosis and Treatment

In an enlightening discussion, Professor Andrew Shaw from the University of Exeter introduces a groundbreaking diagnostic test developed by Attomarker that could transform the way we diagnose and treat Long Covid. Professor Shaw, a seasoned physical chemist with over 20 years of experience in immunity testing and antibodies, explains how a simple finger prick of blood can reveal gaps in a patient’s antibody spectrum. These gaps indicate the specific Covid-19 variant to which a patient had an insufficient antibody response, potentially leading to the chronic symptoms associated with Long Covid. By identifying these gaps, the Attomarker test allows for targeted treatment, either through monoclonal antibodies or appropriate vaccines, to help patients combat the lingering effects of the virus.

While still in the early stages and currently seeking funding for full-scale trials, the results from initial tests are promising. Professor Shaw shares the compelling story of one patient who has shown significant recovery using this innovative approach. The episode delves into the intricate theories of antibody responses to Covid-19 strains, the impact of vaccines, and the potential that the Attomarker test holds for providing a solid diagnostic tool and effective treatment strategy for Long Covid. This breakthrough could be a crucial moment in managing and overcoming the long-term impacts of the pandemic. Well worth a listen.

Listen Here